Maintenance imatinib in Ph+ ALL – pro
There is literature support for maintenance imatinib after stem cell translplntaiton for Ph+ ALL. The Couban panel concluded: ” No study has examined the impact on disease control of tkis used upon achievement of cr, but the panel recommended continuing therapy until disease progression or transplantation, provided that the tki is well tolerated.”
Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.Chen H.J Hematol Oncol. 2012 Jun 8;5:29.
S. Couban e tal, Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome–positive or BCR-ABL–positive acute lymphoblastic leukemia: a Canadian consensus. Curr Oncol. 2014 Apr; 21(2): e265–e309.